United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - cilostazol (unii: n7z035406b) (cilostazol - unii:n7z035406b) - cilostazol 100 mg - cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. cilostazol is contraindicated in patients with: - heart failure of any severity: cilostazol and several of its metabolites are inhibitors of phosphodiesterase iii. several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class iii-iv heart failure. - hypersensitivity to cilostazol or any components of cilostazol tablets (e.g., anaphylaxis, angioedema). teratogenic effects pregnancy category c . cilostazol has been shown to be teratogenic in rats at doses that are greater than 5-times the human mrhd on a body surface area basis. there are no adequate and well-controlled studies in pregnant women. in a rat developmental toxicity study, oral administration of 1000 mg cilostazol/kg/day was associated with decreased fetal weights, and increased incidences of cardiovascular, renal, and skeletal anomalies (ventricular se

United States - English - NLM (National Library of Medicine)

a-s medication solutions - tretinoin (unii: 5688utc01r) (tretinoin - unii:5688utc01r) - tretinoin gel and cream are indicated for topical application in the treatment of acne vulgaris. the safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established. use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - prazosin hydrochloride (unii: x0z7454b90) (prazosin - unii:xm03yj541d) - prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - cilostazol (unii: n7z035406b) (cilostazol - unii:n7z035406b) - cilostazol 50 mg - cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. cilostazol tablets are contraindicated in patients with: - heart failure of any severity: cilostazol and several of its metabolites are inhibitors of phosphodiesterase iii. several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class iii-iv heart failure. - hypersensitivity to cilostazol or any components of cilostazol tablets (e.g., anaphylaxis, angioedema) teratogenic effects cilostazol has been shown to be teratogenic in rats at doses that are greater than 5-times the human mrhd on a body surface area basis. there are no adequate and well-controlled studies in pregnant women. in a rat developmental toxicity study, oral administration of 1000 mg cilostazol/kg/day was associated with decreased fetal weights, and increased incidences of cardiovascular, renal, and skeletal anomalies (ventricular septal, aortic ar

United States - English - NLM (National Library of Medicine)

bayer healthcare llc. - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e) - aspirin 81 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - montelukast sodium - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - montelukast sodium - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

torrent pharma (uk) ltd - montelukast sodium - oral tablet - 10mg

United States - English - NLM (National Library of Medicine)

cardinal health 107, llc - lamotrigine (unii: u3h27498ks) (lamotrigine - unii:u3h27498ks) - adjunctive therapy lamotrigine is indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older: monotherapy lamotrigine is indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (aed). safety and effectiveness of lamotrigine have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from aeds other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant aeds. lamotrigine is indicated for the maintenance treatment of bipolar i disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy [see clinical studies (14.2)]. limitations of use treatment of

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - rivastigmine (unii: pki06m3iw0) (rivastigmine - unii:pki06m3iw0) - rivastigmine transdermal system is indicated for the treatment of dementia of the alzheimer's type (ad). efficacy has been demonstrated in patients with mild, moderate, and severe alzheimer's disease. rivastigmine transdermal system is indicated for the treatment of mild-to-moderate dementia associated with parkinson's disease (pdd). rivastigmine transdermal system is contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation [see description (11)] . - previous history of application site reactions with rivastigmine transdermal patch suggestive of allergic contact dermatitis [see warnings and precautions (5.3)] . isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . risk summary there are no adequate data on the developmental risks associated with the use of rivastigmine transdermal system in pregnant women. in animals, no adverse effects on embryo-fetal d